Intelligence Unit Special Reports Special Events Subscribe Sponsored Departments Follow Us

Twitter Facebook LinkedIn RSS

Oral Cancer Drugs Deserve Parity



Oral cancer drugs account for 25% to 35% of the drugs in the cancer drug pipeline. But their high costs are causing some cancer patients to avoid them. It's time for health plans to treat these drugs like injectable cancer-fighting medications.


Name:
E-mail:
Website:  
Please enter your comment below:
Please enter the text below: